$917 Million is the total value of Fairmount Funds Management LLC's 15 reported holdings in Q1 2024. The portfolio turnover from Q4 2023 to Q1 2024 was 31.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXSM | AXSOME THERAPEUTICS INC | $188,334,145 | +0.3% | 2,360,077 | 0.0% | 20.53% | +3.4% | |
| NUVALENT INC | $144,520,166 | +2.0% | 1,924,626 | 0.0% | 15.75% | +5.3% | ||
| Sell | APOGEE THERAPEUTICS INC | $136,132,593 | +65.7% | 2,048,647 | -30.3% | 14.84% | +70.9% | |
| Buy | DIANTHUS THERAPEUTICS INC | $82,885,110 | +313.3% | 2,762,837 | +43.3% | 9.04% | +326.4% | |
| KNSA | Buy | KINIKSA PHARMACEUTICALS LTD | $63,231,513 | +25.0% | 3,204,841 | +11.2% | 6.89% | +29.0% |
| Buy | ENLIVEN THERAPEUTICS INC | $56,337,217 | +91.0% | 3,202,798 | +50.3% | 6.14% | +97.0% | |
| ASTRIA THERAPEUTICS INC | $50,024,366 | +83.3% | 3,554,129 | 0.0% | 5.45% | +89.1% | ||
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $32,320,186 | +8.3% | 1,845,813 | +34.8% | 3.52% | +11.8% |
| MRUS | MERUS N V | $32,297,948 | +63.7% | 717,254 | 0.0% | 3.52% | +69.0% | |
| COGT | Buy | COGENT BIOSCIENCES INC | $31,756,308 | +51.7% | 4,725,641 | +32.8% | 3.46% | +56.6% |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $26,959,578 | – | 931,890 | +100.0% | 2.94% | – |
| TYRA BIOSCIENCES INC | $22,850,596 | +18.4% | 1,393,329 | 0.0% | 2.49% | +22.2% | ||
| GERN | New | GERON CORP | $22,000,001 | – | 6,666,667 | +100.0% | 2.40% | – |
| SPYRE THERAPEUTICS INC | $14,353,509 | +76.3% | 378,421 | 0.0% | 1.56% | +82.0% | ||
| TERN | TERNS PHARMACEUTICALS INC | $13,382,400 | +1.1% | 2,040,000 | 0.0% | 1.46% | +4.3% | |
| ARGX | Exit | ARGENX SEsponsored adr | $0 | – | -112,903 | -100.0% | -4.54% | – |
| Exit | RAYZEBIO INC | $0 | – | -1,245,929 | -100.0% | -8.18% | – | |
| IMGN | Exit | IMMUNOGEN INC | $0 | – | -5,929,592 | -100.0% | -18.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AXSOME THERAPEUTICS INC | 18 | Q2 2024 | 24.6% |
| ARGENX SE | 17 | Q4 2023 | 9.3% |
| COGENT BIOSCIENCES INC | 15 | Q2 2024 | 7.2% |
| VIRIDIAN THERAPEUTICS INC | 14 | Q2 2024 | 6.3% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| NUVALENT INC | 12 | Q2 2024 | 17.1% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | June 13, 2024 | 11,330,141 | 9.9% |
| Spyre Therapeutics, Inc. | April 25, 2024 | 4,024,541 | 10.0% |
| Apogee Therapeutics, Inc. | April 01, 2024 | 4,762,558 | 10.0% |
| Dianthus Therapeutics, Inc. /DE/ | April 01, 2024 | 2,950,487 | 10.0% |
| Viridian Therapeutics, Inc.\DE | April 01, 2024 | 13,956,685 | 18.6% |
| Annexon, Inc. | February 14, 2024 | 322,893 | 0.4% |
| Astria Therapeutics, Inc. | February 14, 2024 | 3,633,965 | 9.9% |
| Axsome Therapeutics, Inc. | February 14, 2024 | 2,360,077 | 4.9% |
| Enliven Therapeutics, Inc. | February 14, 2024 | 2,131,369 | 5.2% |
| Kiniksa Pharmaceuticals, Ltd. | February 14, 2024 | 2,883,221 | 8.1% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4/A | 2024-09-17 |
| 4 | 2024-09-17 |
| SC 13D/A | 2024-09-17 |
| 4 | 2024-09-16 |
| 4 | 2024-09-13 |
| SC 13D/A | 2024-09-13 |
| 3 | 2024-09-12 |
| 3 | 2024-09-06 |
| SC 13D | 2024-09-06 |
| N-PX | 2024-09-03 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.